Testing a new drug called NLG802 with temozolomide in children with brain tumors that are growing
Original title: Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test in people, done mainly to check safety.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether a new drug called NLG802 is safe for children with brain tumors when it is given with a chemotherapy drug called temozolomide.
Who this trial is for. This trial is for children with primary brain tumors that are getting worse. It tests NLG802, a drug taken by mouth that is still being studied, given along with temozolomide chemotherapy. The dose of NLG802 is raised step by step in the study.
Where it stands. There are no results yet. This trial is measuring how safe NLG802 is, how well children can handle it, and how the body takes in and clears the drug. The answers are not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: If your child has a brain tumor that is growing, this is one study that exists. You can ask your child's care team about it. They can tell you if it fits your child's situation and if it is worth looking into.
What it doesn't mean: This does not mean NLG802 works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that anyone will be helped. It is not a promise of a cure. Whether a child can join is decided by the trial team.
Source: ClinicalTrials.gov, July 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.